Navigation Links
JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program

PALO ALTO, Calif., March 14, 2007 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that the Journal of the of Cardiology (JACC) has published data from the Ranolazine Open Label Experience (ROLE) program, which showed long-term therapy with Ranexa(R) (ranolazine extended-release tablets) to be safe and well tolerated in patients with chronic stable angina who completed one of two phase 3 clinical trials, and enrolled in the ROLE program.

These data also suggest no evidence of increased mortality attributable to Ranexa based on two year survival rates of ROLE participants compared with published outcomes of similar cohorts used as a reference population.

Because ROLE was an open label study, and not a placebo controlled clinical trial with a comparator group, it does not allow for a rigorous analysis for mortality and it is difficult to fully characterize the implications of the deaths reported in the study.

The ROLE program evaluated 746 patients with chronic angina who chose to receive Ranexa(R) following their participation in the phase 3 Monotherapy Assessment of Ranolazine In Stable Angina (MARISA) or the phase 3 Combination Assessment of Ranolazine In Stable Angina (CARISA) clinical studies with Ranexa. More than 85 percent of eligible MARISA patients and more than 80 percent of eligible CARISA patients chose to receive Ranexa in the ROLE program.

The mean duration of follow-up was 2.82 years and more than 75 percent of ROLE patients completed at least two years of Ranexa therapy. Two years after initial dosing, 9.7 percent of patients had discontinued Ranexa due to adverse events.

No treatment discontinuations occurred due to QT prolongation and no cases of torsades de pointes were reported. The most commonly reported adverse events, other than angina, were dizziness (11.8 percent) and constipation (10.9 percent).

"The high rate of patients choosing
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
2. Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
3. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
4. The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
5. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
6. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
7. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
8. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
9. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
10. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
11. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
Post Your Comments:
(Date:7/30/2015)... 30, 2015  NanoSmart Pharmaceuticals, Inc., a private ... received Orphan Drug Designation from the Food and ... that uses NanoSmart,s proprietary drug delivery platform. The ... the treatment of Ewing,s sarcoma, a rare type ... Orphan Drug Designation on the basis of a ...
(Date:7/30/2015)... July 30, 2015 /PRNewswire/ - Anything Technologies Media, Inc. ... Frontier Indoor Garden Solutions (FIGS), www.frontiergarden.com ... and the Project Manager for a My Compassion ... American Group located in Alaska.  The project will ... its finance Teaming Partners. The first phase of ...
(Date:7/30/2015)... 2015  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific ... quarter 2015 financial results and provide a corporate update. ... Global Select Market closes that day. The ... domestic callers and 914.495.8552 for international callers. Please specify ...
Breaking Medicine Technology:NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Frontier Indoor Garden Solutions announced as Horticultural Supplier and Project Manager for Alaskan Tribal Medical Marijuana Grow Facility 2Frontier Indoor Garden Solutions announced as Horticultural Supplier and Project Manager for Alaskan Tribal Medical Marijuana Grow Facility 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4
... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today announced ... Health Care Conference. Piper Jaffray Health Care Conference ... 2:00 p.m. ET A ... at http://www.avanir.com . About Avanir Pharmaceuticals, ...
... 2011  Cara Therapeutics, Inc. today announced the initiation ... an oral formulation of its peptide-based, kappa opioid ... trial is expected to enroll up to 60 ... evaluate the pharmacokinetic, pharmacodynamic and safety profile of ...
Cached Medicine Technology:Cara Therapeutics Initiates Phase I Study with Oral Formulation of Novel Peripherally-Acting Kappa Opioid Agonist 2
(Date:7/30/2015)... ... 30, 2015 , ... Ross A. Clevens, MD, FACS has been ... of Plastic Surgery. This is Dr. Clevens’ second appointment by the prestigious school. ... developing a strong presence and a valuable mentoring program for medical students. ...
(Date:7/30/2015)... ... July 30, 2015 , ... Western University of Health Sciences ... Special Olympics World Games, the largest sports and humanitarian event in the world this ... , The World Games, held July 25 through August 2, 2015, benefited from the ...
(Date:7/30/2015)... ... 30, 2015 , ... Ocean Hills Recovery has officially been accredited by CARF ... No recommendations means CARF found no areas in the OHR program that needed improvement, ... of all facilities receive. In addition, Ocean Hills was granted the maximum certification period ...
(Date:7/30/2015)... ... 30, 2015 , ... New research finds some distinct differences in the way ... on the Surviving Mesothelioma website. , Researchers with the National Institutes of Health, ... cases of mesothelioma occurring between 1990 and 2010. Two percent of these cases (207) ...
(Date:7/30/2015)... ... 30, 2015 , ... Political unrest is the number one ... new survey by leading international insurance provider Clements Worldwide. The "Clements Worldwide Risk ... the largest sources of financial losses among respondents. , Twenty-eight percent of top ...
Breaking Medicine News(10 mins):Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3
... blood sugar namely blindness, malfunction of the kidneys are known. ... have now come out with astonishing details that a raise ... than 100 adults with type 1 diabetes hwo had four ... mouth, having a sweet taste in their mouth and needing ...
... the globe as 95% of the AIDS victims dwell ... Special Session on HIV/AIDS, physicians demanded to bring down ... the AIDS victims in developing countries. ,Dr. Anne-Valerie ... as Medicines Sans Frontieres, or MSF), MSF provides healthcare ...
... Heart Association's 41st Annual Conference on Cardiovascular Disease Epidemiology ... new cousin counterpart to heart disease-Asthma. It is found ... ,Carlos Iribarren, MD, MPH, PhD, of Kaiser Permanente, in ... had a risk of 33% towards developing the heart ...
... number of psychological benefits, including fighting stress-related physical and ... found no psychological benefit from the use of ginseng. ... the sport and exercise psychology lab at the Oregon ... Engles, PhD, conducted the study and found that there ...
... the major cause of morbidity in most of the ... reluctant to take extra vitamins or iron pills, as ... were effective for improving the iron status of young ... iron deficiency in children of low-to-middle income groups. These ...
... is an inherited disease of the nervous system due ... causing symptoms such as involuntary movements and balance problems ... speech as well. ,All these days, until now, ... a mutated form of the protein 'huntingtin' which is ...
Cached Medicine News:Health News:Asthma! A new warning for heart disease 2
Reptilase-Time from Bothrops atrox...
Pefakit PiCT UFH Controls...
Pefakit PiCT LMWH Calibrators...
APTT (Ellagic Acid) - 10 ml...
Medicine Products: